Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility

References

• Ministero della Giustizia. Detenuti presenti - aggiornamento al 30 giugno 2022. 2022 Jun 30.
   Google Scholar
• Pattavina A, Palmieri MJ. Fears of COVID-19 contagion and the Italian prison system response. Victims Offenders. 2020;15(7–8):1124–8. doi:10.1080/15564886.2020.1813856.
   Web of Science ®Google Scholar
• Tavoschi L, Monarca R, Giuliani R, Saponaro A, Petrella S, Ranieri R, Alves da Costa F, Ferreira-Borges C, Montanari L. Prevention and control of COVID-19 in Italian prisons: stringent measures and unintended consequences. Front Public Health. 2020;8:559135. doi:10.3389/fpubh.2020.559135.
   PubMed Web of Science ®Google Scholar
• WHO. Preparedness, prevention and control of COVID-19 in prisons and other places of detention. 2021 Feb 8.
   Google Scholar
• Wright NM, Hearty P, Allgar V. Prison primary care and non-communicable diseases: a data-linkage survey of prevalence and associated risk factors. BJGP Open. 2019;3(2). doi:10.3399/bjgpopen19X101643.
   PubMedGoogle Scholar
• di Giacomo E, de Girolamo G, Peschi G, Fazel S, Clerici M. Italian prisons during the COVID-19 outbreak. Am J Public Health. 2020;110(11):1646–47. doi:10.2105/AJPH.2020.305896.
   PubMed Web of Science ®Google Scholar
• Kinner SA, Young JT, Snow K, Southalan L, Lopez-Acuna D, Ferreira-Borges C, O’Moore E. Prisons and custodial settings are part of a comprehensive response to COVID-19. Lancet Public Health. 2020;5(4):e188–89. doi:10.1016/S2468-2667(20)30058-X.
   PubMed Web of Science ®Google Scholar
• Leibowitz AI, Siedner MJ, Tsai AC, Mohareb AM. Association between prison crowding and COVID-19 incidence rates in Massachusetts prisons, April 2020-January 2021. JAMA Intern Med. 2021;181(10):1315–21. doi:10.1001/jamainternmed.2021.4392.
   PubMed Web of Science ®Google Scholar
• Brinkley-Rubinstein L, Peterson M, Martin R, Chan P, Berk J. Breakthrough SARS-CoV-2 infections in prison after vaccination. N Engl J Med. 2021;385(11):1051–52. doi:10.1056/NEJMc2108479.
   PubMed Web of Science ®Google Scholar
• Cingolani M, Caraceni L, Cannovo N, Fedeli P. The COVID-19 epidemic and the prison system in Italy. J Correct Health Care. 2021;27(1):3–7. doi:10.1089/jchc.20.04.0026.
   PubMed Web of Science ®Google Scholar
• Neufeld M, Alves da Costa F, Ferreira-Borges C. Prisons need to be included in global and national vaccinations effort against COVID-19. Lancet Reg Health Eur. 2021;4:100088. doi:10.1016/j.lanepe.2021.100088.
   PubMedGoogle Scholar
• Montoya-Barthelemy AG, Lee CD, Cundiff DR, Smith EB. COVID-19 and the correctional environment: the American prison as a focal point for public health. Am J Prev Med. 2020;58(6):888–91. doi:10.1016/j.amepre.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Strassle C, Jardas E, Ochoa J, Berkman BE, Danis M, Rid A, Taylor HA. Covid-19 vaccine trials and incarcerated people - the ethics of inclusion. N Engl J Med. 2020;383(20):1897–99. doi:10.1056/NEJMp2025955.
   PubMed Web of Science ®Google Scholar
• Vella R, Giuga G, Piizzi G, Alunni Fegatelli D, Petroni G, Tavone AM, Potenza S, Cammarano A, Mandarelli G, Marella GL. Health management in Italian prisons during COVID-19 outbreak: a focus on the second and third wave. Healthcare (Basel). 2022;10(2). doi:10.3390/healthcare10020282.
   Google Scholar
• Esposito M, Salerno M, Di Nunno N, Ministeri F, Liberto A, Sessa F. The risk of COVID-19 infection in prisons and prevention strategies: a systematic review and a new strategic protocol of prevention. Healthcare (Basel). 2022;10(2). doi:10.3390/healthcare10020270.
   Google Scholar
• Stufano A, Buonvino N, Trombetta CM, Pontrelli D, Marchi S, Lobefaro G, De Benedictis L, Lorusso E, Carofiglio MT, Vasinioti VI, et al. COVID-19 outbreak and BNT162b2 mRNA vaccination coverage in a correctional facility during circulation of the SARS-CoV-2 Omicron BA.1 variant in Itlay. Vaccines (Basel). 2022;10(7). doi:10.3390/vaccines10071137.
   Web of Science ®Google Scholar
• World Health Organization. Tracking SARS-CoV-2 variants. 2020. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
   Google Scholar
• Duong D. Alpha, beta, delta, gamma: what’s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;193(27):E1059–60. doi:10.1503/cmaj.1095949.
   PubMed Web of Science ®Google Scholar
• Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract. 2021;11(4):778–84. doi:10.3390/clinpract11040093.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant: technical brief and priority actions for Member States. 2020.
   Google Scholar
• Trombetta CM, Marchi S, Viviani S, Manenti A, Benincasa L, Ruello A, Bombardieri E, Vicenti I, Zazzi M, Montomoli E. Serum neutralizing activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 variants of concern in hospitalized COVID-19 patients. Viruses. 2021;13(7). doi:10.3390/v13071347.
   Web of Science ®Google Scholar
• Thakur V, Ratho RK. OMICRON (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol. 2022;94(5):1821–24. doi:10.1002/jmv.27541.
   PubMed Web of Science ®Google Scholar
• Stufano A, Buonvino N, Cagnazzo F, Armenise N, Pontrelli D, Curzio G, De Benedictis L, Lovreglio P. Efficacy of the measures adopted to prevent COVID-19 outbreaks in an Italian correctional facility for inmates affected by chronic diseases. Front Public Health. 2021;9:694795. doi:10.3389/fpubh.2021.694795.
   PubMed Web of Science ®Google Scholar
• Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, Marchi S, Montomoli E. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 2020;92(10):2096–104. doi:10.1002/jmv.25986.
   PubMed Web of Science ®Google Scholar
• Berk J, Del Pozo B, Rich JD, Lee JD. Injecting opioid use disorder treatment in jails and prisons: the potential of extended-release buprenorphine in the carceral setting. J Addict Med. 2022;16(4):396–98. doi:10.1097/ADM.0000000000000942.
   PubMed Web of Science ®Google Scholar
• Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184(23):5699–714 e11. doi:10.1016/j.cell.2021.10.011.
   PubMed Web of Science ®Google Scholar
• Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Assessment of neutralizing antibody response against SARS-CoV-2 variants after 2 to 3 doses of the BNT162b2 mRNA COVID-19 vaccine. JAMA Netw Open. 2022;5(5):e2210780. doi:10.1001/jamanetworkopen.2022.10780.
   PubMed Web of Science ®Google Scholar
• Sanchez-Sendra B, Albert E, Zulaica J, Torres I, Gimenez E, Botija P, Beltran MJ, Rodado C, Geller R, Navarro D. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci Rep. 2022;12(1):3788. doi:10.1038/s41598-022-07849-2.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Piccini G, Pierleoni G, Leonardi M, Dapporto F, Marchi S, Andreano E, Paciello I, Benincasa L, Lovreglio P, et al. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. Commun Biol. 2022;5(1):903. doi:10.1038/s42003-022-03849-0.
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, Burger JA, Oomen M, Bouhuijs JH, van Vught LA, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. PLoS Med. 2022;19(5):e1003991. doi:10.1371/journal.pmed.1003991.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–83 e9. doi:10.1016/j.cell.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–25. doi:10.1038/s41591-021-01285-x.
   PubMed Web of Science ®Google Scholar
• Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602(7898):682–88. doi:10.1038/s41586-022-04399-5.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–66.e4. doi:10.1016/j.cell.2021.12.033.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, Bruxvoort KJ, Tubert JE, Florea A, Ku JH, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and delta variants. Nat Med. 2022;28(5):1063–71. doi:10.1038/s41591-022-01753-y.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou D, Nutalai R, Duyvesteyn HME, Tuekprakhon A, Ginn HM, Dejnirattisai W, Supasa P, Mentzer AJ, Wang B, et al. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host Microbe. 2022;30(1):53–68 e12. doi:10.1016/j.chom.2021.11.013.
   PubMed Web of Science ®Google Scholar
• Ao D, Lan T, He X, Liu J, Chen L, Baptista-Hon DT, Zhang K, Wei X. SARS-CoV-2 Omicron variant: immune escape and vaccine development. MedComm (2020). 2022;3(1):e126. doi:10.1002/mco2.126.
   Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and Their emerging variants with escape mutations. Front Immunol. 2022;13:801522. doi:10.3389/fimmu.2022.801522.
   PubMed Web of Science ®Google Scholar
• Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021;55:101533. doi:10.1016/j.smim.2021.101533.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Consortium C-GU, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24. doi:10.1038/s41579-021-00573-0.
   PubMed Web of Science ®Google Scholar
• Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses. 2021;13(7). doi:10.3390/v13071192.
   PubMed Web of Science ®Google Scholar
• Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–41. doi:10.1038/s41586-021-03412-7.
   PubMed Web of Science ®Google Scholar
• Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA. 2021;325(18):1896–98. doi:10.1001/jama.2021.4388.
   PubMed Web of Science ®Google Scholar
• Hernandez-Luis P, Aguilar R, Pelegrin-Perez J, Ruiz-Olalla G, Garcia-Basteiro AL, Tortajada M, Moncunill G, Dobano C, Angulo A, Engel P. Decreased and heterogeneous neutralizing antibody responses against RBD of SARS-CoV-2 variants after mRNA vaccination. Front Immunol. 2022;13:816389. doi:10.3389/fimmu.2022.816389.
   PubMed Web of Science ®Google Scholar
• Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529–39 e3. doi:10.1016/j.chom.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184(11):2939–54 e9. doi:10.1016/j.cell.2021.03.055.
   PubMed Web of Science ®Google Scholar
• Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–61. doi:10.1016/S2666-5247(21)00267-6.
   PubMedGoogle Scholar
• Perez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;28(3):481–85. doi:10.1038/s41591-022-01705-6.
   PubMed Web of Science ®Google Scholar